Treatments

Dose-response relationship of oral treprostinil for secondary endpoints in the FREEDOM-EV study
R James White, E Grünig, C Jerjes-Sanchez D, G M Bohns Meyer, T Pulido, P Sepulveda, K Y Wang, C Q Deng, R Grover, D Solum, A Ousmanou, V F Tapson

European Respiratory Journal Sep 2019, 54 (suppl 63) PA5462; DOI: 10.1183/13993003.congress-2019.PA5462
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Luca Richeldi, Simon Walsh, Susanne Stowasser, Carl Coeck, Rainer-Georg Goeldner, Emmanuelle Clerisme-Beaty, Rozsa Schlenker-Herceg, Kevin K. Brown

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT1881; DOI: 10.1183/13993003.congress-2019.RCT1881
Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
Peter D’Andrea, Oliver Kornmann, Janos Mucsi, Motokazu Kato, Lorraine Bandelli, Biswajit Sen

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT3780; DOI: 10.1183/13993003.congress-2019.RCT3780
Therapeutic limitations of oral medications to normalize hemodynamics in patients with pulmonary artery hypertension
Hiroto Shimokawahara, Hiromi Matsubara, Kazuna Hayashi, Takahiro Nishihara, Masahiro Tsuji, Takanori Naito, Masataka Shigetoshi, Isao Tabuchi, Mitsuru Munemasa

European Respiratory Journal Sep 2019, 54 (suppl 63) PA5467; DOI: 10.1183/13993003.congress-2019.PA5467
Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough
Akio Niimi, Hiroyuki Ishihara, Hideaki Hida, Sayaka Miyazaki

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT452; DOI: 10.1183/13993003.congress-2019.RCT452
Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
Kristin B. Highland, Arata Azuma, Aryeh Fischer, Masataka Kuwana, Toby M. Maher, Maureen D. Mayes, Ganesh Raghu, Mannaig Girard, Margarida Alves, Martina Gahlemann, Oliver Distler

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT1882; DOI: 10.1183/13993003.congress-2019.RCT1882
Late Breaking Abstract - Comparison of mesh and jet nebulizers with different interfaces in acute moderate to severe paediatric asthma
Gerald Moody

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT3781; DOI: 10.1183/13993003.congress-2019.RCT3781
Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)
Toby Maher, Tamera J. Corte, Aryeh Fischer, Michael Kreuter, David J. Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg, Vincent Cottin

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT1880; DOI: 10.1183/13993003.congress-2019.RCT1880
Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension
Roham Zamanian, David Badesch, Lorinda Chung, Robyn Domsic, Thomas Medsger, Ashley Pinckney, Lynette Keyes-Elstein, Carla D’Aveta, Meagan Spychala, James White, Paul Hassoun, Fernando Torres, Jerry Molitor, Dinesh Khanna, Holden Maeker, Beverly Welch, Ellen Goldmuntz, Mark Nicolls, - On Behalf Of Asco1 Investigators

European Respiratory Journal Sep 2019, 54 (suppl 63) RCT1884; DOI: 10.1183/13993003.congress-2019.RCT1884
National survey of physiotherapy and speech and language therapists’ practice for patients with refractory chronic cough in England: Treatment
Sarah Chamberlain Mitchell, Jemma Haines, Jacky Smith, Anand Pandyan

European Respiratory Journal Sep 2019, 54 (suppl 63) PA5254; DOI: 10.1183/13993003.congress-2019.PA5254

Main menu

User menu

Search

Treatments

Pages

Contact us